Boceprevir

Boceprevir
Clinical data
Trade names	Victrelis
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a611039
License data	EU EMA: by INN; US FDA: Boceprevir;
Routes of; administration	Oral
ATC code	J05AP03 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	75%
Elimination half-life	3.4 hours
Identifiers
	IUPAC name (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide;
CAS Number	394730-60-0 ;
PubChem CID	10324367;
IUPHAR/BPS	7876;
DrugBank	DB08873 ;
ChemSpider	8499830 ;
UNII	89BT58KELH;
KEGG	D08876 ;
ChEMBL	ChEMBL218394 ;
NIAID ChemDB	398493;
CompTox Dashboard (EPA)	DTXSID30960103 ;
ECHA InfoCard	100.226.246
Chemical and physical data
Formula	C27H45N5O5
Molar mass	519.687 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N3[C@H](C(=O)NC(C(=O)C(=O)N)CC1CCC1)[C@H]2C(C)([C@H]2C3)C)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C;
	InChI InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1 ; Key:LHHCSNFAOIFYRV-DOVBMPENSA-N ;

Boceprevir (INN, trade name Victrelis) is a protease inhibitor used to treat hepatitis caused by hepatitis C virus (HCV) genotype 1. It binds to the HCV nonstructural protein 3 active site.

It was initially developed by Schering-Plough, then by Merck after it acquired Schering in 2009. It was approved by the FDA in May 2011. In January 2015, Merck announced that they would be voluntarily withdrawing Victrelis from the market due to the overwhelming superiority of newer direct-acting antiviral agents, such as ledipasvir/sofosbuvir.